Aduro BioTech’s (ADRO) “Buy” Rating Reaffirmed at Oppenheimer

Aduro BioTech (NASDAQ:ADRO)‘s stock had its “buy” rating restated by research analysts at Oppenheimer in a research report issued on Tuesday.

A number of other research analysts have also recently issued reports on ADRO. Zacks Investment Research raised shares of Aduro BioTech from a “hold” rating to a “buy” rating and set a $2.75 price target for the company in a research report on Wednesday, December 5th. HC Wainwright reissued a “buy” rating and set a $8.30 price target on shares of Aduro BioTech in a research report on Wednesday, December 19th. Finally, BidaskClub raised shares of Aduro BioTech from a “sell” rating to a “hold” rating in a research report on Thursday, February 14th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $7.41.

Shares of NASDAQ ADRO opened at $3.91 on Tuesday. Aduro BioTech has a 1 year low of $2.34 and a 1 year high of $9.85. The stock has a market cap of $310.87 million, a P/E ratio of -3.37 and a beta of 2.08.

Aduro BioTech (NASDAQ:ADRO) last issued its quarterly earnings results on Wednesday, February 27th. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.10). Aduro BioTech had a negative net margin of 632.05% and a negative return on equity of 54.84%. As a group, equities analysts anticipate that Aduro BioTech will post -0.78 earnings per share for the current year.

In other Aduro BioTech news, insider Elsas Andrea Van sold 6,844 shares of the firm’s stock in a transaction dated Tuesday, February 26th. The shares were sold at an average price of $4.25, for a total transaction of $29,087.00. Following the completion of the sale, the insider now directly owns 245,638 shares in the company, valued at approximately $1,043,961.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last 90 days, insiders have sold 10,658 shares of company stock valued at $38,889. 5.00% of the stock is owned by company insiders.

A number of large investors have recently added to or reduced their stakes in ADRO. Baillie Gifford & Co. increased its stake in Aduro BioTech by 19.0% during the 4th quarter. Baillie Gifford & Co. now owns 3,661,173 shares of the biotechnology company’s stock valued at $9,665,000 after purchasing an additional 584,348 shares in the last quarter. Artal Group S.A. increased its stake in Aduro BioTech by 81.8% during the 4th quarter. Artal Group S.A. now owns 1,000,000 shares of the biotechnology company’s stock valued at $2,640,000 after purchasing an additional 450,000 shares in the last quarter. BlackRock Inc. increased its stake in Aduro BioTech by 8.8% during the 3rd quarter. BlackRock Inc. now owns 5,121,243 shares of the biotechnology company’s stock valued at $37,640,000 after purchasing an additional 414,717 shares in the last quarter. Two Sigma Investments LP increased its stake in Aduro BioTech by 1,227.1% during the 4th quarter. Two Sigma Investments LP now owns 445,929 shares of the biotechnology company’s stock valued at $1,177,000 after purchasing an additional 412,327 shares in the last quarter. Finally, Vanguard Group Inc increased its stake in Aduro BioTech by 9.9% during the 3rd quarter. Vanguard Group Inc now owns 4,029,445 shares of the biotechnology company’s stock valued at $29,617,000 after purchasing an additional 362,516 shares in the last quarter. Institutional investors and hedge funds own 44.73% of the company’s stock.

About Aduro BioTech

Aduro BioTech, Inc, an immunotherapy company, focuses on the discovery, development, and commercialization of therapies that transform the treatment of challenging diseases. The company is developing ADU-S100, which is in Phase I monotherapy study, as well as in Phase 1b combination study with an anti-PD1 immune checkpoint inhibitor; ADU-214 that is in Phase I clinical trials for the treatment of lung cancer; and ADU-741 for the treatment of prostate cancer.

Recommended Story: Do stock splits help investors?

Analyst Recommendations for Aduro BioTech (NASDAQ:ADRO)

Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.